

## 1026 pramlintide

- Assistance with ambulation during beginning therapy
- Testing for diabetes mellitus, acromegaly if receiving long-term therapy
- **Pregnancy/breastfeeding:** use only if benefits outweigh fetal risk, may cause fetal harm; do not breastfeed

### Evaluate:

- Therapeutic response: movement disorder improves

### Teach patient/family:

- That therapeutic effects may take several weeks to a few months
- To change positions slowly to prevent orthostatic hypotension
- **To use product exactly as prescribed; if product is discontinued abruptly, parkinsonian crisis may occur; to avoid alcohol, OTC sleeping products**
- To notify prescriber if pregnancy is planned or suspected
- To notify prescriber of impulse control disorders: shopping

### HIGH ALERT

#### pramlintide (Rx)

(pram'lin-tide)

SymlinPen

*Func. class.:* Antidiabetic

*Chem. class.:* Synthetic human amylin analog

**ACTION:** Modulates and slows stomach emptying, prevents postprandial rise in plasma glucagon, decreases appetite, leads to decreased caloric intake and weight loss

**USES:** As an adjunct prandial to insulin therapy for uncontrolled type 1 or type 2 diabetes

**CONTRAINDICATIONS:** Hypersensitivity to this product or cresol; gastroparesis

**Black Box Warning:** Hypoglycemia

**Precautions:** Pregnancy, breastfeeding, osteoporosis, thyroid disease, trauma, vomiting, renal failure, fever, diarrhea

## DOSAGE AND ROUTES

### Type 1 diabetes

• **Adult:** **SUBCUT** 15 mcg before each meal ( $\geq 30$  g carbohydrate), titrate up in 15-mcg increments to target dose of 60 mcg/dose; each dose titration should occur after no nausea for 3 days

### Type 2 diabetes

• **Adult:** **SUBCUT** 60 mcg before each meal ( $\geq 30$  g CHO), titrate up to 120 mcg **SUBCUT** with each meal after no nausea for 3-7 days

**Available forms:** PEN 60, 120 (1000 mcg/mL solution for injection)

### Administer:

- Store at room temperature for  $\leq 30$  days; keep away from heat and sunlight; refrigerate all other supply
- Premeal insulin should be decreased by 50% when starting and adjusted to therapeutic dose to prevent hypoglycemia

### SUBCUT route

- Rotate injection sites, allow solution to warm to room temperature before use
- Take immediately before mealtime or if 30 g of carbohydrates will be consumed
- Do not use if a meal is skipped
- Do not use if discolored; do not give in arm; absorption is variable

## SIDE EFFECTS

**CNS:** *Headache*, fatigue, dizziness, confusion

**EENT:** Blurred vision

**GI:** *Nausea, vomiting, anorexia*, abdominal pain

**INTEG:** Inj-site reactions, diaphoresis

**META:** Hypoglycemia

**MS:** Arthralgia

**RESP:** *Cough*, pharyngitis

**SYST:** *Systemic allergy*

## PHARMACOKINETICS

Bioavailability 30%-40%, not extensively bound to blood cells or albumin, 40% bound in plasma, half-life 48 min, metabolized by kidneys, peak 20 min, duration 3 hr